Koyfin Home > Directory > Health Care > Aratana Theraptcs

Aratana Theraptcs Price Chart PETX

Historical daily share price chart and data for Aratana Theraptcs since 2013 adjusted for splits and dividends. The latest closing price for Aratana Theraptcs as of July 17, 2019 is $4.92.
  • In 2019 the stock opened at $6.07 and closed at $4.92 for a loss of -23%.
  • In 2018 the stock opened at $5.26 and closed at $6.13 for a gain of 14%.
  • In 2017 the stock opened at $7.29 and closed at $5.26 for a loss of -39%.
  • In 2016 the stock opened at $5.43 and closed at $7.18 for a gain of 24%.
View Chart On Koyfin

Aratana Theraptcs Summary

Stock Symbol: PETX

Aratana Theraptcs Company Info

Aratana Therapeutics, Inc., a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States. Its product portfolio includes small molecule therapeutics and therapeutic candidates. The company markets NOCITA, a post-operative analgesia for cranial cruciate ligament surgery in dogs; ENTYCE for appetite stimulation in dogs; GALLIPRANT for the control of pain and inflammation associated with osteoarthritis in dogs; and canine osteosarcoma vaccine, live listeria vector for the treatment of dogs diagnosed with osteosarcoma in the United States. It is also developing NOCITA, a bupivacaine liposome injectable suspension for post-operative pain in cats; AT-002, a specific formulation of capromorelin for use in cats; AT-018, an oral CRTH2 antagonist for the treatment of atopic dermatitis in dogs; AT-006, an anti-viral eprociclovir that is used for the treatment of feline herpes virus-induced ophthalmic conditions in cats; AT-016, allogeneic adipose-derived stem cells for dogs; and AT-019, an EP4 receptor antagonist therapeutic candidate with potential in pain, inflammation, and other indications. In addition, the company develops AT-008, a therapeutic candidate for treating canine lymphoma in dogs; and other therapeutics for dogs and cats in Europe. It has collaboration agreement with Elanco Animal Health, Inc. to develop, manufacture, and commercialize GRAPIPRANT products; Pacira Pharmaceuticals, Inc. to develop and commercialization of licensed animal health products for NOCITA; and AskAt Inc for the development and commercialization of compound AT-019. Aratana Therapeutics, Inc. was founded in 2010 and is headquartered in Leawood, Kansas. As of July 18, 2019, Aratana Therapeutics, Inc. operates as a subsidiary of Elanco Animal Health Incorporated.
Market Cap
Dividend Yield
0 %
Beta vs SPX
Short Interest
76.37 %
30D Volatility
Hedge Fund Held
14.43 %

Last 10 Days of PETX Prices